Exclusive worldwide license agreement

First financing round closed

2A Pharma AB today closed its first financing round, raising SEK 27 million from private angel investors. This new capital will enable us to take our first project, the AAVLP-HPV vaccine, through to the end of phase I clinical studies. We are grateful for our...
Exclusive worldwide license agreement

2A Pharma is a reality

2A Pharma AB was incorporated in Sweden on 12 December 2016. Søren Nielsen, CEO: “This marks the formal beginning of a new exciting venture and the team is very excited about the journey ahead.”